Please try another search
Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252, a POZ conjugate for the treatment of Parkinson’s disease. The company also develops SER 227 for long-acting pain relief; SER 214 to treat Parkinson’s disease; and SER 228 for the treatment of epilepsy. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. Serina Therapeutics, Inc. was founded in 2006 and is based in Huntsville, Alabama.
Name | Age | Since | Title |
---|---|---|---|
J. Milton Harris | 83 | 2024 | Director |
Steven A. Ledger | 65 | 2024 | Interim CEO & Director |
Balkrishan Gill | 59 | 2024 | Executive Chairman |
Remy Gross | 54 | 2024 | Director |
Richard Marshall | 57 | 2024 | Director |
Charles Warren Olanow | - | - | Member of Scientific Advisory Board |
Steven Michael Mintz | 58 | 2024 | Director |
Gregory H. Bailey | 68 | 2024 | Director |
William K. Schmidt | 73 | - | Member of Scientific Advisory Board |
Gaurav Sahay | - | - | Member of Scientific Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review